<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33328403</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1349-7235</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Internal medicine (Tokyo, Japan)</Title>
          <ISOAbbreviation>Intern Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic Cerebellar Degeneration and Lambert-Eaton Myasthenic Syndrome with SOX-1 Antibodies.</ArticleTitle>
        <Pagination>
          <StartPage>1607</StartPage>
          <EndPage>1610</EndPage>
          <MedlinePgn>1607-1610</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2169/internalmedicine.5934-20</ELocationID>
        <Abstract>
          <AbstractText>A 69-year-old man was admitted to our hospital for progressive muscle weakness in both lower limbs and limb ataxia (day 0). Nerve conduction studies showed low compound muscle action potential amplitudes at rest and increased amplitudes after maximum voluntary contraction. Blood testing revealed SOX-1 antibodies. He was diagnosed with paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome (PCD-LEMS). He died from aspiration pneumonia on day 9. Small-cell lung carcinoma (SCLC), which had not been obvious on computed tomography, was found during the autopsy. Patients with PCD-LEMS who test positive for SOX-1 antibodies should be carefully evaluated for SCLC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wada</LastName>
            <ForeName>Shinichi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Kansai Electric Power Hospital, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kamei</LastName>
            <ForeName>Mayu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Kansai Electric Power Hospital, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uehara</LastName>
            <ForeName>Naoko</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Kansai Electric Power Hospital, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Neurology, Kansai Electric Power Medical Research Institute, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsuzaki</LastName>
            <ForeName>Koji</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Kansai Electric Power Hospital, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Neurology, Kansai Electric Power Medical Research Institute, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamano</LastName>
            <ForeName>Toshiaki</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Kansai Electric Power Hospital, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Neurology, Kansai Electric Power Medical Research Institute, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Intern Med</MedlineTA>
        <NlmUniqueID>9204241</NlmUniqueID>
        <ISSNLinking>0918-2918</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015624" MajorTopicYN="Y">Lambert-Eaton Myasthenic Syndrome</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="Y">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055752" MajorTopicYN="Y">Small Cell Lung Carcinoma</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Lambert-Eaton myasthenic syndrome</Keyword>
        <Keyword MajorTopicYN="N">SOX-1 antibodies</Keyword>
        <Keyword MajorTopicYN="N">autopsy</Keyword>
        <Keyword MajorTopicYN="N">paraneoplastic cerebellar degeneration</Keyword>
        <Keyword MajorTopicYN="N">small cell lung carcinoma</Keyword>
      </KeywordList>
      <CoiStatement>
        <b>The authors state that they have no Conflict of Interest (COI).</b>
      </CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>5</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33328403</ArticleId>
        <ArticleId IdType="pmc">PMC8188018</ArticleId>
        <ArticleId IdType="doi">10.2169/internalmedicine.5934-20</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ. Lambert-Eaton myasthenic syndrome. Neuro Clin
36: 379-394, 2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6690495</ArticleId>
            <ArticleId IdType="pubmed">29655456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sutton I, Winer JB. The immunopathogenesis of paraneoplastic neurological syndromes. Clin Sci
102: 475-486, 2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11980564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stich O, Klages E, Bischler P, et al. . SOX antibodies in sera from patients with paraneoplastic neurological syndromes. Acta Neurol Scand
125: 326-331, 2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21751968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakao YK, Motomura M, Fukudome T, et al. . Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology
59: 1773-1775, 2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12473768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titulaer MJ, Wirtz PW, Kuks JBM, et al. . The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol
201-202: 153-158, 2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18644631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koriyama H, Kyoraku I, Yamashita S, Shiomi K, Matsumoto N, Nakazato M. Synchronous appearance and improvement with anticancer chemotherapy of paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome complicated with small cell lung cancer. Rinsho Shinkeigaku
53: 104-108, 2013.  (in Japanese, Abstract in English).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23470889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lipka AF, Verschuuren JJGM, Titulaer MJ. SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma. Ann N Y Acad Sci
1275: 70-77, 2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23278580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tschernatsch M, Gross O, Kneifel N, Kaps M, Blaes F. SOX-1 autoantibodies in patients with paraneoplastic neurological syndromes. Autoimmun Rev
8: 549-551, 2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19393214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabater L, Titulaer M, Saiz A, Verschuuren A, Gure AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology
70: 924-928, 2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18032743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabater L, Hoftberger R, Boronat A, Saiz A, Dalmau J, Graus F. Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer. PLoS One
8: e60438, 2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3607586</ArticleId>
            <ArticleId IdType="pubmed">23536908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titulaer MJ, Klooster R, Potman M, et al. . SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Incol
27: 4260-4267, 2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19667272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berger B, Dersch R, Ruthardt E, Rasiah C, Rauer S, Stich O. Prevalence of anti-SOX-1 reactivity in various neurological disorders. J Neurol Sci
369: 342-346, 2016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27653921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toyoda Y, Nakayama T, Kusunoki Y, Iso H, Suzuki T. Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography. Br J Cancer
98: 1602-1607, 2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2391122</ArticleId>
            <ArticleId IdType="pubmed">18475292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miki S, Nomura Y, Hayashi N, et al. . Prospective study of spatial distribution of missed lung nodules by readers in CT lung screening using computer-assisted detection. Acad Radiol. Forthcoming.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32305166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanamori K, Yahata T, Otsuka K, Imanaka M, Yokota I. A case of small cell lung carcinoma without apparent primary lesion accompanying Lambert-Eaton myasthenic syndrome. Nihon Kokyuki Gakkai Zasshi
47: 1151-1155, 2009.  (in Japanese, Abstract in English).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20058696</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33328403</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1349-7235</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Internal medicine (Tokyo, Japan)</Title>
          <ISOAbbreviation>Intern Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic Cerebellar Degeneration and Lambert-Eaton Myasthenic Syndrome with SOX-1 Antibodies.</ArticleTitle>
        <Pagination>
          <StartPage>1607</StartPage>
          <EndPage>1610</EndPage>
          <MedlinePgn>1607-1610</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2169/internalmedicine.5934-20</ELocationID>
        <Abstract>
          <AbstractText>A 69-year-old man was admitted to our hospital for progressive muscle weakness in both lower limbs and limb ataxia (day 0). Nerve conduction studies showed low compound muscle action potential amplitudes at rest and increased amplitudes after maximum voluntary contraction. Blood testing revealed SOX-1 antibodies. He was diagnosed with paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome (PCD-LEMS). He died from aspiration pneumonia on day 9. Small-cell lung carcinoma (SCLC), which had not been obvious on computed tomography, was found during the autopsy. Patients with PCD-LEMS who test positive for SOX-1 antibodies should be carefully evaluated for SCLC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wada</LastName>
            <ForeName>Shinichi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Kansai Electric Power Hospital, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kamei</LastName>
            <ForeName>Mayu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Kansai Electric Power Hospital, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uehara</LastName>
            <ForeName>Naoko</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Kansai Electric Power Hospital, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Neurology, Kansai Electric Power Medical Research Institute, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsuzaki</LastName>
            <ForeName>Koji</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Kansai Electric Power Hospital, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Neurology, Kansai Electric Power Medical Research Institute, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamano</LastName>
            <ForeName>Toshiaki</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Kansai Electric Power Hospital, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Neurology, Kansai Electric Power Medical Research Institute, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Intern Med</MedlineTA>
        <NlmUniqueID>9204241</NlmUniqueID>
        <ISSNLinking>0918-2918</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015624" MajorTopicYN="Y">Lambert-Eaton Myasthenic Syndrome</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="Y">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055752" MajorTopicYN="Y">Small Cell Lung Carcinoma</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Lambert-Eaton myasthenic syndrome</Keyword>
        <Keyword MajorTopicYN="N">SOX-1 antibodies</Keyword>
        <Keyword MajorTopicYN="N">autopsy</Keyword>
        <Keyword MajorTopicYN="N">paraneoplastic cerebellar degeneration</Keyword>
        <Keyword MajorTopicYN="N">small cell lung carcinoma</Keyword>
      </KeywordList>
      <CoiStatement>
        <b>The authors state that they have no Conflict of Interest (COI).</b>
      </CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>5</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33328403</ArticleId>
        <ArticleId IdType="pmc">PMC8188018</ArticleId>
        <ArticleId IdType="doi">10.2169/internalmedicine.5934-20</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ. Lambert-Eaton myasthenic syndrome. Neuro Clin
36: 379-394, 2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6690495</ArticleId>
            <ArticleId IdType="pubmed">29655456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sutton I, Winer JB. The immunopathogenesis of paraneoplastic neurological syndromes. Clin Sci
102: 475-486, 2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11980564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stich O, Klages E, Bischler P, et al. . SOX antibodies in sera from patients with paraneoplastic neurological syndromes. Acta Neurol Scand
125: 326-331, 2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21751968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakao YK, Motomura M, Fukudome T, et al. . Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology
59: 1773-1775, 2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12473768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titulaer MJ, Wirtz PW, Kuks JBM, et al. . The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol
201-202: 153-158, 2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18644631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koriyama H, Kyoraku I, Yamashita S, Shiomi K, Matsumoto N, Nakazato M. Synchronous appearance and improvement with anticancer chemotherapy of paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome complicated with small cell lung cancer. Rinsho Shinkeigaku
53: 104-108, 2013.  (in Japanese, Abstract in English).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23470889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lipka AF, Verschuuren JJGM, Titulaer MJ. SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma. Ann N Y Acad Sci
1275: 70-77, 2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23278580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tschernatsch M, Gross O, Kneifel N, Kaps M, Blaes F. SOX-1 autoantibodies in patients with paraneoplastic neurological syndromes. Autoimmun Rev
8: 549-551, 2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19393214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabater L, Titulaer M, Saiz A, Verschuuren A, Gure AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology
70: 924-928, 2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18032743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabater L, Hoftberger R, Boronat A, Saiz A, Dalmau J, Graus F. Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer. PLoS One
8: e60438, 2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3607586</ArticleId>
            <ArticleId IdType="pubmed">23536908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titulaer MJ, Klooster R, Potman M, et al. . SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Incol
27: 4260-4267, 2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19667272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berger B, Dersch R, Ruthardt E, Rasiah C, Rauer S, Stich O. Prevalence of anti-SOX-1 reactivity in various neurological disorders. J Neurol Sci
369: 342-346, 2016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27653921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toyoda Y, Nakayama T, Kusunoki Y, Iso H, Suzuki T. Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography. Br J Cancer
98: 1602-1607, 2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2391122</ArticleId>
            <ArticleId IdType="pubmed">18475292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miki S, Nomura Y, Hayashi N, et al. . Prospective study of spatial distribution of missed lung nodules by readers in CT lung screening using computer-assisted detection. Acad Radiol. Forthcoming.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32305166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanamori K, Yahata T, Otsuka K, Imanaka M, Yokota I. A case of small cell lung carcinoma without apparent primary lesion accompanying Lambert-Eaton myasthenic syndrome. Nihon Kokyuki Gakkai Zasshi
47: 1151-1155, 2009.  (in Japanese, Abstract in English).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20058696</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
